Receptor tyrosine kinase inhibitors in thyroid cancer

Maria Domenica Castellone, Francesca Carlomagno, Giuliana Salvatore, Massimo Santoro

Research output: Contribution to journalArticlepeer-review


Thyroid cancer is frequently associated with the oncogenic conversion of receptor tyrosine kinases (RTKs) or their downstream signalling molecules. Hence, there is a strong biological rationale for assessing the efficacy of RTK blockade to treat patients who are resistant to or not candidates for treatment with radioactive iodine. The first results of clinical trials based on the use of RTK inhibitors in thyroid cancer patients have recently been published. Here we discuss targeting of specific RTKs as a potential therapeutic strategy for the treatment of thyroid cancer.

Original languageEnglish
Pages (from-to)1023-1038
Number of pages16
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Issue number6
Publication statusPublished - Dec 2008


  • kinase
  • monoclonal antibody
  • small-molecule inhibitor
  • thyroid

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Receptor tyrosine kinase inhibitors in thyroid cancer'. Together they form a unique fingerprint.

Cite this